**Table 1: Characteristics of pregnant women (n=201)**

|  |  |
| --- | --- |
| **Characteristics** | **n** |
| Mean age, years (SD) | 27.7 (4.8) |
| Median parity (IQR) | 2 (1-2) |
| Median gravidity (IQR) | 2 (1-3) |
| Median gestational age at booking, weeks (IQR) | 20 (16-24) |
| Median gestational age at interview, weeks (IQR) | 32 (24-32) |
| Median CD4+ cell count, cells/mm3 (IQR) | 395 (294-500) |
| \*When HIV status discovered: |  |
| current pregnancy | 143 (71.5) |
| previous pregnancy | 44 (22.0) |
| outside of pregnancy | 13 (6.5) |
| \*\*Disclosed HIV status (%) | 175 (87.9) |
| People disclosed to (%): |  |
| partner | 159 (90.9) |
| parent | 61 (34.9) |
| sibling | 42 (24.0) |
| friend | 30 (17.1) |
| other | 5 (2.9) |

SD = standard deviation; IQR = interquartile range

\*discovery of HIV status, n=200; \*\*disclosure, n=199

**Table 2: Characteristics and knowledge of pregnant women who were members of a support group (n=67), vs. those who were not (n=133)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Members of a support group** | **Yes, n (%)** | **No, n (%)** | **p-value** |
| **Characteristics** |  |  |  |
| Age, years |  |  | 0.764 |
| <25 | 18 (26.9) | 35 (26.3) |  |
| 25-35 | 47 (70.1) | 91 (68.4) |  |
| >35 | 2 (3.0) | 7 (5.3) |  |
| Parity |  |  | 0.407 |
| ≤2 | 58 (86.6) | 109 (81.9) |  |
| 3-5 | 9 (13.4) | 24 (18.1) |  |
| When HIV status discovered: |  |  | 0.043 |
| current pregnancy | 44 (65.7) | 98 (74.2) |  |
| previous pregnancy | 21 (31.3) | 23 (17.4) |  |
| outside of pregnancy | 2 (3.0) | 11 (8.3) |  |
| Disclosed HIV status | 56 (83.6) | 118 (88.7) | 0.356 |
| **Correct knowledge on** |  |  |  |
| AZT prophylaxis: |  |  |  |
| indication | 66 (98.5) | 124 (93.2) | 0.143 |
| timing of initiation | 64 (95.5) | 119 (90.2) | 0.188 |
| duration of use | 26 (38.8) | 99 (74.4) | <0.001 |
| Prophylaxis during labour | 18 (26.9) | 69 (51.9) | 0.001 |
| Need for infant prophylaxis | 63 (94.0) | 111 (83.5) | 0.036 |
| Type of infant prophylaxis | 7 (10.5) | 18 (13.5) | 0.553 |
| Duration of infant prophylaxis | 52 (77.6) | 62 (39.1) | <0.001 |
| Duration of exclusive breastfeeding | 59 (88.1) | 87 (65.4) | 0.001 |
| **Overall score** |  |  |  |
| mean (SD) | 5.3 (0.98) | 5.2 (1.41) | 0.542 |

AZT = zidovudine

**Table 3: Difference in knowledge in pregnant women who were already on zidovudine (AZT) prophylaxis (n=114) and those who were not (n=86)**

|  |  |  |  |
| --- | --- | --- | --- |
| **AZT prophylaxis** | **Yes, n (%)** | **No, n (%)** | **p-value** |
| **Correct knowledge on:** |  |  |  |
| Indication for AZT | 111 (97.4) | 79 (91.9) | 0.137 |
| Timing of AZT initiation | 101 (88.6) | 82 (95.4) | 0.125 |
| Duration of use of AZT | 79 (69.3) | 47 (54.7) | 0.034 |
| Intrapartum prophylaxis | 63 (55.3) | 24 (27.9) | <0.001 |
| **Score** |  |  |  |
| mean (SD) | 5.44 (1.18) | 4.94 (1.34) | 0.005 |

**Table 4: Characteristics of healthcare workers (n=80)**

|  |  |
| --- | --- |
| **Characteristics** | **n (%)** |
| \*Gender |  |
| female | 74 (93.7) |
| male | 5 (6.3) |
| Staff categories |  |
| professional nurse | 35 (43.8) |
| auxiliary nurse | 9 (11.3) |
| lay counsellor | 30 (37.5) |
| other | 6 (7.5) |
| Time in current position |  |
| <6 months | 7 (8.8) |
| 6 months – 1 year | 8 (10.0) |
| >1 – 5 years | 33 (41.3) |
| >5 – 10 years | 22 (27.5) |
| >10 years | 10 (12.5) |

\*gender, n=79

**Table 5: Characteristics and knowledge of healthcare workers who were satisfied with their knowledge of PMTCT (n=64), vs. those who were not satisfied (n=16)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Satisfied with knowledge of PMTCT** | **Yes, n (%)** | **No, n (%)** | **p-values** |
| **Characteristics** |  |  |  |
| Staff categories: |  |  |  |
| midwife | 14 (21.9) | 6 (37.5) | -- |
| PMTCT coordinator | 10 (15.6) | 0 (0) | -- |
| PCR nurse | 4 (6.1) | 2 (12.5) | -- |
| lay counsellor | 28 (43.8) | 2 (12.5) | -- |
| other | 8 (12.5) | 6 (37.5) | -- |
| Time in current position: |  |  |  |
| <6 months | 4 (6.3) | 3 (18.8) | -- |
| 6 months – 1 year | 7 (10.9) | 1 (6.3) | -- |
| 2 – 5 years | 30 (46.9) | 3 (18.8) | -- |
| 6 – 10 years | 19 (29.7) | 3 (18.8) | -- |
| >10 years | 4 (6.3) | 6 (37.5) | -- |
| **Correct knowledge on:** |  |  |  |
| Single-dose NVP: |  |  |  |
| efficacy | 55 (85.9) | 11 (68.8) | 0.211 |
| repeat in same pregnancy | 52 (81.3) | 10 (62.5) | 0.410 |
| use in subsequent pregnancies | 51 (79.7) | 12 (75.0) | 0.933 |
| ART use in pregnancy | 44 (68.8) | 8 (50.0) | 0.191 |
| Seroconversion during pregnancy | 42 (65.5) | 10 (62.5) | 0.754 |
| Exclusive breastfeeding and risk of MTCT | 26 (40.6) | 9 (56.3) | 0.190 |
| Extended breastfeeding and risk of MTCT | 50 (78.1) | 12 (75.0) | 0.704 |
| Contraception for HIV-infected women | 19 (29.7) | 1 (6.3) | 0.105 |
| **Overall score** |  |  |  |
| mean (SD) | 5.3 (1.88) | 4.6 (1.63) | 0.157 |

PMTCT = prevention of mother-to-child transmission of HIV; PCR nurse = nurse responsible for HIV PCR tests in infants;

NVP = nevirapine; ART = antiretroviral therapy; MTCT = mother-to-child transmission of HIV